A platform-technology company that provides devices, diagnostics, infection control and imaging for specialists treating a wide range of gastrointestinal diseases.
“The River Cities team has been insightful and supportive throughout the challenges of launching a new business and the subsequent rapid growth of our company. They understand the key elements of successful strategy, collaboration and the art of getting things done. River Cities is an extremely valuable partner to our company,” says Mark Gilreath, CEO, EndoChoice.
Medtech company EndoChoice Holdings has introduced the third-generation Fuse full spectrum endoscopy system.
On June 5, EndoChoice Holdings Inc. (NYSE:GI), completed an IPO, raising nearly $106 million on the New York Stock Exchange. River Cities Fund IV first invested in EndoChoice in 2008 and is the second-largest stakeholder in the company.
EndoChoice announced the close of a $57 million financing. Proceeds will go toward continued expansion of sales and marketing efforts of the Fuse Full Spectrum Endoscopy platform.
EndoChoice has been named as one of “Atlanta’s Best and Brightest Companies to Work For™”, a designation that hundreds of companies pursue. EndoChoice was identified as a company that delivers exceptional human resource practices as measured by the National Association for Business Resources.